FDA Panel Rejects Sintilimab Clinical Trial Data From China

The new drug for lung cancer had clinical trial data only from China; FDA officials made clear their opposition to using studies conducted in only one nation as a basis for drug approvals.
Medscape Medical News

source https://www.medscape.com/viewarticle/968320?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost